Stock Events

Stock Events

Protagenic Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q1 2022
Next
-2.58
-2.24
-1.91
-1.58
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBP.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes plc operates in the brain health area, including treatments for depression and schizophrenia, overlapping with Protagenic's focus on mental health disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
ACADIA Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurotherapeutics field.
BridgeBio Pharma
BBIO
Mkt Cap13.29B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs that could compete with Protagenic's approach to treating mental health disorders.
Axsome Therapeutics
AXSM
Mkt Cap10.62B
Axsome Therapeutics develops novel therapies for central nervous system disorders including depression, directly competing with Protagenic's therapeutic focus.
Insmed
INSM
Mkt Cap28.76B
Insmed Incorporated works on rare diseases, including neurological disorders, potentially competing with Protagenic's research and development focus.
Neurocrine Biosciences
NBIX
Mkt Cap13.25B
Neurocrine Biosciences focuses on neurological and endocrine diseases, including treatments for mental health disorders, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries has a broad portfolio that includes CNS treatments, potentially competing across several of Protagenic's target areas.

About

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Show more...
CEO
Dr. Garo H. Armen Ph.D.
Employees
1
Country
United States
ISIN
US74365N3017

Listings

MU
DE
MBP.MU
OTC Link
US
PTIX
XNAS
US
PTIXW

0 Comments

Share your thoughts

FAQ

What is Protagenic Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protagenic Therapeutics stocks are traded under the ticker MBP.MU.
When is the next Protagenic Therapeutics earnings date?▼
Protagenic Therapeutics is going to release the next earnings report on June 03, 2026.
How many employees does Protagenic Therapeutics have?▼
As of May 06, 2026, the company has 1 employees.
In which sector is Protagenic Therapeutics located?▼
Protagenic Therapeutics operates in the Health & Wellness sector.
When did Protagenic Therapeutics complete a stock split?▼
Protagenic Therapeutics has not had any recent stock splits.
Where is Protagenic Therapeutics headquartered?▼
Protagenic Therapeutics is headquartered in Santa Barbara, United States.